



Docket No.: AVSI-0027 (108328.00161)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ruxandra Draghia-Akli, et al.

Serial No.: 10/699,597


Filed: October 30, 2003

Group: 1645

For: **SYNTHETIC MUSCLE PROMOTERS WITH ACTIVITIES EXCEEDING
NATURALLY OCCURRING REGULATORY SEQUENCES IN CARDIAC CELLS**

Mail Stop: Petition
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:




RESPONSE TO NOTICE OF ABANDONMENT UNDER 37 CFR 1.53 (F) OR (G)

In response to the Notice of Abandonment Under 37 CFR 1.53 (F) or (G) mailed March 14, 2007, enclosed please find the following documents:

1. Petition to Withdraw a Holding of Abandonment Based on Failure to Receive an Office Action under 37 CFR §1.181(a);
2. Copy of Notice of Abandonment under 37 CFR 1.53(f) or (g) [Exhibit A];
3. Copy of Withdrawal of Previously Sent Notice/ Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures retrieved from the USPTO PAIR System [Exhibit B];
4. Statement from Practitioner in Support of Petition to Withdraw Holding of Abandonment Based on Failure to Receive Office Action;
5. Copy of docket record for Docket No. 108328.00161 [Exhibit C];
6. Amendment under 37 CFR §1.111;
7. Sequence Listing Statement Under 37 CFR §1.821(f);
8. Revised Sequence Listing on paper; and
9. Revised Sequence Listing on CD.

The commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 10-0096.

Respectfully Submitted,



May 21, 2007

T. Ling Chwang

Reg. No. 33,590

Jackson Walker L.L.P.

901 Main Street, Suite 6000


Dallas, Texas 75202

Tel: (214) 953-5959

Fax: (214) 661-6870

Attorney Docket No.:
AVS1-0027 (108328.00161)

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ruxandra Draghia-Akli, et al.

Serial No.: 10/699,597

Filed: October 30, 2003

For: **SYNTHETIC MUSCLE PROMOTERS WITH ACTIVITIES
EXCEEDING NATURALLY OCCURRING REGULATORY
SEQUENCES IN CARDIAC CELLS**

Group No.: 1645

Examiner: Kaushal, Sumesh

Mail Stop: Petition
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

CERTIFICATE OF MAILING: I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on 5-21-07

Tracy S. Giroux
(Printed or typed name of person signing the certificate)

Tracy S. Giroux
(Signature of the person signing the certificate)

AMENDMENT UNDER 37 C.F.R. § 1.111

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures dated July 6, 2006, please enter the enclosed Sequence Listing. In addition, please amend the above-identified patent application as follows. No new matter has been added.

In the Sequence Listing:

Please replace the original Sequence Listing in the Specification with the replacement Sequence Listing as indicated on the Sequence Listing sheets (pages 1-24) that are part of the Statement under 37 C.F.R. §1.821(f) having the heading SEQUENCE LISTING:

In the Specification, please replace paragraphs [0005] and [0051] as follows:

Please amend Paragraph [0005] and Paragraph [0051] as follows. Certain original text contains underlining in the nucleotide sequence and this amendment simply adds of sequence identifiers. No new matter has been added.

Paragraph [0005]

[0005] The molecular mechanisms controlling cardiac-specific gene transcription requires the dissection of the cis-elements that govern the complex spatio-temporal expression of these genes. The vertebrate heart is formed during fetal development following a series of complex morphogenetic events that require the functional presence of different proteins, tightly regulated by combinatorial interactions of several transcription factors and their cofactors (Nemer and Nemer, 2001; Wang et al., 2001). First, the proximal serum response element (SRE) ('5-CC[A/T]₆GG-3'), SEQ ID NO:23, of the skeletal α -actin promoter was incorporated. Multiple SREs are found in the cardiac, skeletal and smooth muscle α -actin promoters (Chang et al., 2001), and in the promoters of myosin light chain and dystrophin (Bergsma et al., 1986; Carroll et al., 1986). This cis-element is recognized by the trans-acting serum response factor (SRF), and by the competitive inhibitor YY1 (Chow and Schwartz, 1990; Lee et al., 1992; Minty and Kedes, 1986). Serum response factor (SRF) is a key regulator of a number of extracellular signal-regulated genes important for cell growth and differentiation (Zhang et al., 2001). Mutations in the proximal SRE that block SRF binding abolish skeletal α -actin promoter (SK) activity, indicating a fundamental role for this promoter element. Second, MEF-2 sites ('5-[C/T]TAAAAATAAC[C/T]₃-3'), SEQ ID NO: 24, that have been found in

the promoter/enhancer regions of the myosin light-chain 3 gene were selected. A single MEF-2 site lacks enhancer activity, but has multiple copies that exhibit strong enhancer activity (Gossett et al., 1989). Mutation of the MEF2 site severely reduced promoter activity in embryos, underlining the importance of MEF2 in controlling differentiation in all muscle lineages (Kelly et al., 2002). Third, the MEF-1 sites ('5-CANNTG-3'), or E-boxes that are found in the upstream regulatory region of most, if not all, muscle-specific genes were included (Olson et al., 1991; Weintraub et al., 1990). MEF-1 sites are recognized by the basic helix-loop-helix (bHLH) family of proteins. Multiple MEF-1 sites placed upstream of basal non-muscle promoters are sufficient to direct muscle-specific expression and MyoD-mediated trans-activation in transient assays (Lassar et al., 1991; Weintraub et al., 1990). Finally, the highly conserved muscle-CAT motif, or TEF-1 binding site ('5-CATTCCT-3') was selected. TEF-1 mediates both muscle-specific (SK, cardiac troponin T, cardiac α - and β -myosin heavy chain) and non-muscle specific transcription (simian virus 40 promoter) (Larkin et al., 1996; Stewart et al., 1994).

Paragraph [0051]

[0051] Different combination of SRE, MEF-1, MEF-2 and TEF-1 were then ligated in a total volume of 100 μ l using different molar ratio (Figure 1), maintaining a constant total amount of oligonucleotide of 200 pmoles. The core motif of each regulatory element (underlined) was flanked by adjacent sequence so that the binding sites of the regulatory elements would face the same side of the DNA helix when assembled together. The ligation reaction was completed with T4 ligase in 150 μ l. After ligation, the combination of elements was run on a 6% acrylamide gel. The 75-300-bp region was cut and eluted in 2 volumes of diffusion buffer at 37⁰C overnight. The DNA was extracted using Qiaex II Gel Extraction Kit (Qiagen Inc., Chatsworth, CA, USA) and incubated in 150 μ l with phosphorylated and annealed Sp1 element (2.5 nmoles) and 10U of T4 ligase at 16⁰C overnight. Since each of the Sp1 elements ('5-CCGTCCGCCCTCGG-3'), SEQ ID NO: 25, contains EagI half at both ends, an intact EagI restriction site was generated wherever two Sp1 elements were ligated together. The reaction was cleaned up (Qiaquick Nucleotide Removal Kit), digested with EagI and cloned into the EagI site of SK144GL-2 luciferase reporter construct, which resulted in a

Attorney Docket No.:
AVSI-0027 (108328.00161)

PATENT


library of randomized synthetic-promoter-recombinants that were operatively linked to a reporter gene. The clones that gave the best results in the transfection studies were sequenced automatically.

REMARKS


Applicants have amended the Sequence Listing to contain sequence identifiers for each of the sequences disclosed on page 4, lines 3 and 12, and page 18, line 17, of the Specification. Additionally, Applicants have enclosed replacement copies of the Sequence Listing in both paper and electronic format. The replacement copies contain a Statement under 37 C.F.R. §1.821 indicating that the paper and electronic copies are identical.

If the Examiner has any other matters which pertain to this Application, the Examiner is encouraged to contact the undersigned to resolve these matters by Examiner's Amendment where possible.

Respectfully submitted,



T. Ling Chwang
Registration No. 33,590
JACKSON WALKER L.L.P.
901 Main Street, Suite 6000
Dallas, Texas 75202
Tel: (214) 953-5959
Fax: (214) 661-6870



Date

Docket No. AVSI-0027 (108328.00161)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ruxandra Draghia-Akli, et al.

Serial No.: 10/699,597

Filing Date: October 30, 2003

For: SYNTHETIC MUSCLE PROMOTERS WITH ACTIVITIES EXCEEDING
NATURALLY OCCURRING REGULATORY SEQUENCES IN CARDIAC
CELLS

**PETITION TO WITHDRAW HOLDING OF ABANDONMENT BASED ON FAILURE TO
RECEIVE OFFICE ACTION UNDER 37 CFR 1.181(A)**

Mail Stop: Petition
Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8: I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on 5-21-07

Tracy S. Gibaux
(Printed or typed name of person signing the certificate)

Tracy S. Gibaux
(Signature of the person signing the certificate)

Dear Sir:

Applicants, through their undersigned attorney, the Practitioner, hereby petition the U.S. Patent and Trademark Office ("USPTO") to withdraw the holding of abandonment in this application. A Notice of Abandonment, mailed March 14, 2007 [Exhibit A], was received by the Practitioner on March 16, 2007. A subsequent review of the file history in the USPTO Patent Application Information Retrieval System revealed a Withdrawal of Previously Sent Notice/Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures ("Withdrawal of Previously Sent Notice") was supposedly mailed on July 6, 2006 [Exhibit B]. This Withdrawal of Previously Sent Notice had never been received by the Practitioner. Applicants respectfully request that, since the Withdrawal of Previously Sent Notice was not received by the Practitioner, the Notice of Abandonment be withdrawn.

Docket No. AVSI-0027 (108328.00161)

The following documents are attached in support of this petition:


1. Statement From Practitioner in Support of Petition to Withdraw Holding of Abandonment Based on Failure to Receive Office Action; and
2. Copy of docket record for Docket No. 108328.00161 [Exhibit C] showing **no** evidence of a Withdrawal of Previously Sent Notice being received by the Practitioner or a Response having been docketed at any time surrounding the deadline for response of August 6, 2006.

Applicants respectfully request that this Petition be granted.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. 10-0096.

Any inquiries regarding this correspondence may be directed to the undersigned at the address or telephone number shown below.

Respectfully submitted,


T. Ling Chwang
Reg. No. 33,590

Jackson Walker L.L.P.
901 Main Street, Suite 6000
Dallas, Texas 75202
Tel: (214) 953-5959
Fax: (214) 661-6870

May 21, 2007

SI-00027 (108328.00161)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ruxandra Draghia-Akli, et al.

Serial No.: 10/699,597

Filed: October 30, 2003


For: **SYNTHETIC MUSCLE PROMOTERS WITH ACTIVITIES
EXCEEDING NATURALLY OCCURRING REGULATORY
SEQUENCES IN CARDIAC CELLS**

Art Unit: 1645

Examiner: Kaushal, Sumesh

Mail Stop: Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:



STATEMENT UNDER 37 C.F.R. § 1.821 (F)

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (e), § 1.821 (f), § 1.821 (g), § 1.825 (b) or § 1.825 (d) respectively, are the same. I also state that the paper and computer readable copies of the Sequence Listing submitted herewith contain no new matter.

Respectfully submitted,

T. Ling Chwang

T. Ling Chwang
Reg. No. 33,590

Date: May 21, 2007

JACKSON WALKER L.L.P.
901 Main Street, Suite 6000
Dallas, TX 75202
Tel: 214-953-5959
Fax: 214-661-6870



SEQUENCE LISTING

<110> Advisys
Baylor College of Medicine

<120> SYNTHETIC MUSCLE PROMOTERS WITH ACTIVITIES EXCEEDING NATURALLY
OCCURRING REGULATORY SEQUENCES IN CARDIAC CELLS

<130> 108328.00161 - AVSI-0027

<140> 10699597

<141> 2003-10-30

<150> US 60/423,536

<151> 2002-11-04

<160> 25

<170> PatentIn version 3.3

<210> 1

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> SRE control elements used in the promoters.

<400> 1

gacacccaaa tatggcgacg g

21

<210> 2

<211> 19

<212> DNA

<213> artificial sequence

<220>

<223> MEF-1 control element used in the promoters

<400> 2

ccaacacctg ctgacctgcc

19

<210> 3

<211> 19

<212> DNA

<213> artificial sequence

<220>

<223> MEF-2 control element used in the promoters.

<400> 3

cgctctaaaa ataactccc

19

<210> 4

<211> 13

<212> DNA

<213> artificial sequence

<220>
 <223> TEF-1 control element used in the promoters.

<400> 4
 caccattcct cac 13

<210> 5
 <211> 335
 <212> DNA
 <213> artificial sequence

<220>
 <223> Nucleic acid sequence of an eukaryotic promoter c5-12.

<400> 5
 cggccgtccg ccttcggcac catcctcacg acacccaaat atggcgacgg gtgaggaatg 60
 gtggggagtt attttttagag cggtgaggaa ggtgggcagg cagcaggtgt tggcgctcta 120
 aaaataactc ccgggagtta ttttttagagc ggaggaatgg tggacacca aatatggcga 180
 cggttcctca cccgtcgcca ttttggttg tccgccctcg gccggggccg cattcctggg 240
 ggccgggcgg tgctcccgcc cgctcgata aaaggctccg gggccggcgg cggcccacga 300
 gctacccgga ggagcgggag gcgccaagct ctaga 335

<210> 6
 <211> 40
 <212> PRT
 <213> artificial sequence

<220>
 <223> This is the artificial sequence for GHRH (1-40)OH.

<220>
 <221> MISC_FEATURE
 <222> (1)..(1)
 <223> Xaa at position 1 may be tyrosine, or histidine

<220>
 <221> MISC_FEATURE
 <222> (2)..(2)
 <223> Xaa at position 2 may be alanine, valine, or isoleucine.

<220>
 <221> MISC_FEATURE
 <222> (15)..(15)
 <223> Xaa at position 15 may be alanine, valine, or isoleucine.

<220>
 <221> MISC_FEATURE
 <222> (27)..(27)
 <223> Xaa at position 27 may be methionine, or leucine.

<220>

<221> MISC_FEATURE
 <222> (28)..(28)
 <223> Xaa at position 28 may be serine or asparagine.

<400> 6

Xaa Xaa Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Xaa Gln
 1 5 10 15

Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Xaa Xaa Arg Gln Gln Gly
 20 25 30

Glu Arg Asn Gln Glu Gln Gly Ala
 35 40

<210> 7
 <211> 3534
 <212> DNA
 <213> artificial sequence

<220>
 <223> Nucleic acid sequence for the HV-GHRH plasmid.

<400> 7
 gttgtaaaac gacggccagt gaattgtaat acgactcact atagggcgaa ttggagctcc 60
 accgcggttg cggccgtccg ccctcggcac catcctcagc acacccaaat atggcgacgg 120
 gtgaggaatg gtggggagtt atttttagag cggtgaggaa ggtgggcagg cagcaggtgt 180
 tggcgctcta aaaataactc ccgggagtta tttttagagc ggaggaatgg tggacaccca 240
 aatatggcga cggttctca cccgtcgcca tatttgggtg tccgccctcg gccggggccg 300
 cattcctggg ggccgggcgg tgctcccgcc cgcctcgata aaaggctccg gggccggcgg 360
 cggccacga gctacccgga ggagcgggag gcgccaagct ctagaactag tggatcccaa 420
 ggcccaactc cccgaaccac tcagggtcct gtggacagct cacctagctg ccatggtgct 480
 ctgggtgttc ttctttgtga tcctcaccct cagcaacagc tccactgct cccacctcc 540
 ccctttgacc ctcaggatgc ggcggcacgt agatgccatc ttcaccaaca gctaccggaa 600
 ggtgctggcc cagctgtccg cccgcaagct gctccaggac atcctgaaca ggcagcaggg 660
 agagaggaac caagagcaag gagcataatg actgcaggaa ttcgatatca agcttatcgg 720
 ggtggcatcc ctgtgacccc tccccagtgc ctctcctggc cctggaagtt gccactccag 780
 tgcccaccag ccttgctcta ataaaattaa gttgcatcat tttgtctgac taggtgtcct 840
 tctataatat tatggggtgg aggggggtgg tatggagcaa ggggcaagtt gggaagacaa 900
 cctgtagggc ctgcgggggtc tattgggaac caagctggag tgcagtggca caatcttggc 960
 tcaactgaat ctccgcctcc tgggttcaag cgattctcct gcctcagcct cccgagttgt 1020

tgggattcca	ggcatgcatg	accaggctca	gctaattttt	gttttttttg	tagagacggg	1080
gtttcaccat	attggccagg	ctggtctcca	actcctaata	tcaggatgat	taccacacct	1140
ggcctcccaa	attgctggga	ttacaggcgt	gaaccaactgc	tcccttccct	gtccttctga	1200
ttttaaaata	actataaccag	caggaggacg	tccagacaca	gcataggcta	cctggccatg	1260
cccaaccggg	gggacatttg	agttgcttgc	ttggcactgt	cctctcatgc	gttgggtcca	1320
ctcagtagat	gcctgttgaa	ttcgataccg	tcgacctcga	ggggggggccc	ggtaccagct	1380
tttgttccct	ttagtggagg	ttaatttcga	gcttggcgta	atcatggtca	tagctgtttc	1440
ctgtgtgaaa	ttgttatccg	ctcacaattc	cacacaacat	acgagccgga	agcataaagt	1500
gtaaagcctg	gggtgcctaa	tgagtgagct	aactcacatt	aattgcgttg	cgctcactgc	1560
ccgctttcca	gtcgggaaac	ctgtcgtgcc	agctgcatta	atgaatcggc	caacgcgcgg	1620
ggagaggcgg	tttgcggtatt	gggcgctctt	ccgcttcttc	gctcactgac	tcgctgcgct	1680
cggtcgttcg	gctgcggcga	gcggtatcag	ctcactcaaa	ggcggttaata	cggttatcca	1740
cagaatcagg	ggataacgca	ggaaagaaca	tgtgagcaaa	aggccagcaa	aaggccagga	1800
accgtaaaaa	ggccgcgttg	ctggcgtttt	tccataggct	ccgccccctt	gacgagcatc	1860
acaaaaatcg	acgctcaagt	cagagggtgc	gaaacccgac	aggactataa	agataaccagg	1920
cgtttcccc	tggaagctcc	ctcgtgcgct	ctcctgttcc	gaccctgccg	cttaccggat	1980
acctgtccgc	ctttctccct	tcgggaagcg	tggcgctttc	tcatagctca	cgctgtagggt	2040
atctcagttc	ggtgtaggtc	gttcgctcca	agctgggctg	tgtgcacgaa	cccccgttc	2100
agcccgaccg	ctgcgcctta	tccggttaact	atcgtcttga	gtccaacccg	gtaagacacg	2160
acttatcgcc	actggcagca	gccactggta	acaggattag	cagagcgagg	tatgtaggcg	2220
gtgctacaga	gttcttgaag	tgggtggccta	actacggcta	cactagaaga	acagtatttg	2280
gtatctgcgc	tctgctgaag	ccagttacct	tcggaaaaag	agttggtagc	tcttgatccg	2340
gcaaacaaac	caccgctggg	agcggtggtt	tttttgtttg	caagcagcag	attacgcgca	2400
gaaaaaaaag	atctcaagaa	gaccccttga	tcttttctac	ggggtctgac	gtcagaaga	2460
actcgtcaag	aaggcgatag	aaggcgatgc	gctgcgaatc	gggagcggcg	ataccgtaaa	2520
gcacgaggaa	gcggctagcc	cattcgccgc	caagctcttc	agcaatatca	cggttagcca	2580
acgctatgtc	ctgatagcgg	tccgccacac	ccagccggcc	acagtcgatg	aatccagaaa	2640
agcggccatt	ttccaccatg	atattcggca	agcaggcatc	gccatgggtc	acgacgagat	2700
cctcgccgtc	gggcatgcgc	gccttgagcc	tggcgaacag	ttcggctggc	gcgagcccct	2760
gatgctcttc	gtccagatca	tcctgatcga	caagaccggc	ttccatccga	gtacgtgctc	2820

gctcgatgcg atgtttcgct tgggtggcga atgggcaggt agccggatca agcgtatgca	2880
gccgccgcat tgcattcagcc atgatggata ctttctcggc aggagcaagg tgagatgaca	2940
ggagatcctg ccccggcact tcgccaata gcagccagtc cttccccgct tcagtgacaa	3000
cgtcgagcac agctgcgcaa ggaacgcccg tcgtggccag ccacgatagc cgcgctgcct	3060
cgtcctgcag ttcattcagg gcaccggaca ggtcgggtctt gacaaaaaga accggggcgcc	3120
cctgcgctga cagccggaac acggcgccat cagagcagcc gattgtctgt tgtgcccagt	3180
catagccgaa tagcctctcc acccaagcgg ccggagaacc tgcgtgcaat ccatcttggt	3240
caatcatgcg aaacgatcct catcctgtct cttgatcaga tcttgatccc ctgcgccatc	3300
agatccttgg cggcaagaaa gccatccagt ttactttgca gggcttcca accttaccag	3360
agggcgcccc agctggcaat tccgggtcgc ttgctgtcca taaaaccgcc cagtctagca	3420
actgttggga agggcgatcg gtgcgggcct cttcgctatt acgccagctg gcgaaagggg	3480
gatgtgctgc aaggcgatta agttgggtaa cgccagggtt ttcccagtca cgac	3534

<210> 8

<211> 3534

<212> DNA

<213> artificial sequence

<220>

<223> Nucleic acid sequence for the TI-GHRH plasmid.

<400> 8

gttgtaaaac gacggccagt gaattgtaat acgactcact atagggcgaa ttggagctcc	60
accgcggtgg cggccgtccg ccctcggcac catcctcacg acacccaaat atggcgacgg	120
gtgaggaatg gtggggagtt atttttagag cgggtaggaa ggtgggcagg cagcaggtgt	180
tggcgctcta aaaataactc ccgggagtta tttttagagc ggaggaatgg tggacaccca	240
aatatggcga cggttcctca ccgctcgcca tatttgggtg tccgccctcg gccggggccg	300
cattcctggg ggccggggcg tgctcccgcc cgctcgata aaaggctccg gggccggcg	360
cggccacga gctacccgga ggagcgggag gcgccaagct ctagaactag tggatcccaa	420
ggcccaactc ccgaaccac tcagggtcct gtggacagct cacctagctg ccatggtgct	480
ctgggtgttc ttctttgtga tcctaccct cagcaacagc tcccactgct cccacctcc	540
ccctttgacc ctcaggatgc ggcggtatat cgatgccatc ttcaccaaca gctaccggaa	600
ggtgctggcc cagctgtccg cccgcaagct gctccaggac atcctgaaca ggcagcaggg	660
agagaggaac caagagcaag gagcataatg actgcaggaa ttcgatatca agcttatcgg	720
ggtggcatcc ctgtgacccc tcccagtgct ctctcctggc cctggaagtt gccactccag	780

tgcccaccag ccttgctcta ataaaattaa gttgcatcat tttgtctgac taggtgtcct	840
tctataatat tatgggggtgg aggggggtgg tatggagcaa ggggcaagtt gggaagacaa	900
cctgtagggc ctgcgggggtc tattgggaac caagctggag tgcagtggca caatcttggc	960
tactgcaat ctccgcctcc tgggttcaag cgattctcct gcctcagcct cccgagttgt	1020
tgggattcca ggcattgcattg accagggtca gctaattttt gtttttttgg tagagacggg	1080
gtttcaccat attggccagg ctggtctcca actcctaata tcaggtgatc taccacctt	1140
ggcctcccaa attgctggga ttacaggcgt gaaccactgc tcccttccct gtccttctga	1200
ttttaaaata actataccag caggaggacg tccagacaca gcataggcta cctggccattg	1260
cccaaccggt gggacatttg agttgcttgc ttggcactgt cctctcatgc gttgggtcca	1320
ctcagtagat gcctgttgaa ttcgataccg tcgacctga gggggggccc ggtaccagct	1380
tttgttccct ttagtgaggg ttaatttcga gcttggcgta atcatgggtca tagctgtttc	1440
ctgtgtgaaa ttgttatccg ctcaaatc cacacaacat acgagccgga agcataaagt	1500
gtaaagcctg gggtgccata tgagtgaagt aactcacatt aattgcgttg cgctcactgc	1560
ccgctttcca gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg	1620
ggagaggcgg tttgcgtatt gggcgctctt ccgcttctc gctcactgac tcgctgcgct	1680
cggtcgttcg gctgcggcga gcggtatcag ctcaactcaa ggcggtata cggttatcca	1740
cagaatcagg ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga	1800
accgtaaaaa ggccgcgttg ctggcgtttt tccataggct ccgccccct gacgagcatc	1860
acaaaaatcg acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg	1920
cgtttcccc tggaagctcc ctctgctgct ctctgttcc gaccctgccg cttaccggat	1980
acctgtccgc ctttctccct tcgggaagcg tggcgctttc tcatagctca cgctgtaggt	2040
atctcagttc ggtgtaggtc gttcgtcca agctgggctg tgtgcacgaa cccccgttc	2100
agcccgaccg ctgcgcctta tccggttaact atcgtcttga gtccaaccg gtaagacacg	2160
acttatcgcc actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg	2220
gtgctacaga gttcttgaag tgggtggccta actacggcta cactagaaga acagtatttg	2280
gtatctgcgc tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg	2340
gcaaacaaac caccgctggg agcgggtggt tttttgtttg caagcagcag attacgcgca	2400
gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagaaga	2460
actcgtcaag aaggcgatag aaggcgatgc gctgcgaatc gggagcggcg ataccgtaaa	2520
gcacgaggaa gcggtcagcc cattcgccgc caagctcttc agcaatatca cgggtagcca	2580

acgctatgtc ctgatagcgg tccgccacac ccagccggcc acagtcgatg aatccagaaa	2640
agcgggccatt ttccaccatg atattcggca agcaggcatc gccatgggtc acgacgagat	2700
cctcgccgtc gggcatgcgc gccttgagcc tggcgaacag ttcggctggc gcgagccct	2760
gatgctcttc gtccagatca tcctgatcga caagaccggc ttccatccga gtacgtgctc	2820
gctcgatgcg atgtttcgtc tgggtgtcga atgggcaggc agccggatca agcgtatgca	2880
gccgccgcat tgcacagcc atgatggata ctttctcggc aggagcaagg tgagatgaca	2940
ggagatcctg ccccggcact tcgccaata gcagccagtc cttcccgtc tcagtgacaa	3000
cgtcgagcac agctgcgcaa ggaacgcccg tcgtggccag ccacgatagc cgcgctgcct	3060
cgtcctgcag ttcattcagg gcaccggaca ggtcggctct gacaaaaaga accgggcgcc	3120
cctgcgctga cagccggaac acggcggcat cagagcagcc gattgtctgt tgtgcccagt	3180
catagccgaa tagcctctcc acccaagcgg ccggagaacc tgcgtgcaat ccatcttggt	3240
caatcatgcg aaacgatcct catcctgtct cttgatcaga tcttgatccc ctgcgccatc	3300
agatccttgg cggcaagaaa gccatccagt ttaacttgca gggcttcca accttaccag	3360
agggcgcccc agctggcaat tccggttcgc ttgctgtcca taaaaccgcc cagtctagca	3420
actgttggga agggcgatcg gtgcgggcct cttcgtatt acgccagctg gcgaaagggg	3480
gatgtgctgc aaggcgatta agttgggtaa cgccagggtt ttcccagtca cgac	3534

<210> 9
 <211> 3534
 <212> DNA
 <213> artificial sequence

<220>
 <223> Nucleic acid sequence for the TV-GHRH plasmid.

<400> 9	
gttgtaaaac gacggccagt gaattgtaat acgactcact atagggcgaa ttggagctcc	60
accgcggtgg cggcggtccg ccctcggcac catcctcacg acacccaaat atggcgacgg	120
gtgaggaatg gtggggagtt atttttagag cgggtaggaa ggtgggcagg cagcagggtg	180
tggcgtctta aaaataactc ccgggagtta tttttagagc ggaggaatgg tggacaccca	240
aatatggcga cggttcctca ccgctcgcca tatttggtg tccgccctcg gccggggccg	300
cattcctggg ggccggggcg tgctcccgcc cgctcgata aaaggctccg gggccggcg	360
cggccacga gctaccgga ggagcgggag gcgccaagct ctagaactag tggatcccaa	420
ggcccaactc cccgaaccac tcagggtcct gtggacagct cacctagctg ccatgggtgt	480
ctgggtgttc ttctttgtga tcctcaccct cagcaacagc tccactgtc cccacctcc	540

ccctttgacc	ctcaggatgc	ggcggatatgt	agatgccatc	ttcaccaaca	gctaccggaa	600
gggtgctggcc	cagctgtccg	cccgcaagct	gctccaggac	atcctgaaca	ggcagcaggg	660
agagaggaac	caagagcaag	gagcataatg	actgcaggaa	ttcgatatca	agcttatcgg	720
gggtggcatcc	ctgtgacccc	tccccagtgc	ctctcctggc	cctggaagtt	gccactccag	780
tgcccaccag	ccttgtccta	ataaaattaa	gttgcatcat	tttgtctgac	taggtgtcct	840
tctataatat	tatgggggtg	aggggggtg	tatggagcaa	ggggcaagtt	gggaagacaa	900
cctgtagggc	ctgcggggtc	tattgggaac	caagctggag	tgagtgagca	caatcttggc	960
tactgcaat	ctccgcctcc	tgggttcaag	cgattctcct	gcctcagcct	cccagattgt	1020
tgggattcca	ggcatgcatg	accaggctca	gctaattttt	gttttttttg	tagagacggg	1080
gtttcaccat	attggccagg	ctggctctcca	actoctaatc	tcaggtgatc	taaccacctt	1140
ggcctcccaa	attgctggga	ttacaggcgt	gaacctactgc	tcccttcctt	gtccttctga	1200
ttttaaaata	actataccag	caggaggacg	tccagacaca	gcataggcta	cctggccatg	1260
cccaaccggt	gggacatttg	agttgcttgc	ttggcactgt	cctctcatgc	gttgggtcca	1320
ctcagtagat	gcctgttgaa	ttcgataccg	tcgacctcga	ggggggggccc	ggtaccagct	1380
tttgttcctt	ttagtgaggg	ttaatttcga	gcttggcgta	atcatggtca	tagctgtttc	1440
ctgtgtgaaa	ttgttatccg	ctcacaattc	cacacaacat	acgagccgga	agcataaagt	1500
gtaaagcctg	gggtgcctaa	tgagtgagct	aactcacatt	aattgcgttg	cgctcactgc	1560
ccgctttcca	gtcgggaaac	ctgtcgtgcc	agctgcatta	atgaatcggc	caacgcgcgg	1620
ggagaggcgg	tttgcgattt	gggcgctctt	ccgcttcctc	gctcactgac	tcgctgcgct	1680
cggtcgttcg	gctgcggcga	gcggtatcag	ctcactcaaa	ggcggtaata	cggttatcca	1740
cagaatcagg	ggataacgca	ggaaagaaca	tgtgagcaaa	aggccagcaa	aaggccagga	1800
accgtaaaaa	ggccgcgctt	ctggcgcttt	tccataggct	ccgccccctt	gacgagcatc	1860
acaaaaatcg	acgctcaagt	cagaggtggc	gaaacccgac	aggactataa	agataccagg	1920
cgtttcccc	tggaagetcc	ctcgtgcgct	ctcctgttcc	gaccctgccg	cttaccggat	1980
acctgtccgc	ctttctccct	tcgggaagcg	tggcgctttc	tcatagctca	cgctgtaggt	2040
atctcagttc	gggtgtaggtc	gttcgctcca	agctgggctg	tgtgcacgaa	ccccccgttc	2100
agcccgaccg	ctgcgcctta	tccgtaact	atcgtcttga	gtccaacccg	gtaagacacg	2160
acttatcgcc	actggcagca	gccactggta	acaggattag	cagagcgagg	tatgtaggcg	2220
gtgctacaga	gttcttgaag	tggtagccta	actacggcta	cactagaaga	acagtatttg	2280
gtatctgcgc	tctgctgaag	ccagttacct	tcggaaaaag	agttggtagc	tcttgatccg	2340

gcaaacaaac caccgctggt agcgggtggtt tttttgtttg caagcagcag attacgcgca	2400
gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagaaga	2460
actcgtcaag aaggcgatag aaggcgatgc gctgcgaatc gggagcggcg ataccgtaaa	2520
gcacgaggaa gcggtcagcc cattcgccgc caagctcttc agcaatatca cgggtagcca	2580
acgctatgtc ctgatagcgg tccgccacac ccagccggcc acagtcgatg aatccagaaa	2640
agcggccatt ttccaccatg atattcggca agcaggcatc gccatgggtc acgacgagat	2700
cctcgccgtc gggcatgcgc gccttgagcc tggcgaacag ttcggctggc gcgagcccct	2760
gatgctcttc gtccagatca tcctgatcga caagaccggc ttccatccga gtacgtgctc	2820
gctcgatgcg atgtttcgct tgggtggtcga atgggcaggc agccggatca agcgtatgca	2880
gccgccgcat tgcacagcc atgatggata ctttctcggc aggagcaagg tgagatgaca	2940
ggagatcctg ccccggcact tcgcccaata gcagccagtc ccttcccgtc tcagtgacaa	3000
cgtcgagcac agctgcgcaa ggaacgcccg tcgtggccag ccacgatagc cgcgctgcct	3060
cgctctgcag ttcatcagg gcaccggaca ggtcggctctt gacaaaaaga accgggcgcc	3120
cctgcgctga cagccggaac acggcggcat cagagcagcc gattgtctgt tgtgccagc	3180
catagccgaa tagcctctcc acccaagcgg ccggagaacc tgcgtgcaat ccatcttgtt	3240
caatcatgcg aaacgatcct catcctgtct cttgatcaga tcttgatccc ctgcgccatc	3300
agatccttgg cggcaagaaa gccatccagt ttactttgca gggcttcca accttaccag	3360
agggcgcccc agctggcaat tccggttcgc ttgctgtcca taaaaccgcc cagtctagca	3420
actgttggga agggcgatcg gtgcgggcct cttegtatt acgccagctg gcgaaagggg	3480
gatgtgctgc aaggcgatta agttgggtaa cgccagggtt ttcccagtca cgac	3534

<210> 10

<211> 3534

<212> DNA

<213> artificial sequence

<220>

<223> Nucleic acid sequence for the 15/27/28 GHRH plasmid.

<400> 10

gttgtaaaac gacggccagt gaattgtaat acgactcact atagggcgaa ttggagctcc	60
accgcggtgg cggccgtccg ccctcggcac catcctcacg acacccaaat atggcgacgg	120
gtgaggaatg gtggggagtt attttttagag cggtgaggaa ggtgggcagg cagcaggtgt	180
tggcgtctta aaaataactc ccgggagtta ttttttagagc ggaggaatgg tggacaccca	240
aatatggcga cggttcctca cccgtcgcca tatttgggtg tccgccctcg gccggggccg	300

cattcctggg	ggccggggcg	tgctcccgcc	cgctcgata	aaaggctccg	gggccggcg	360
cgccccacga	gctacccgga	ggagcgggag	gcgccaagct	ctagaactag	tggatcccaa	420
ggcccaactc	cccgaaccac	tcagggtcct	gtggacagct	cacctagctg	ccatggtgct	480
ctgggtgttc	ttctttgtga	tcctcaccct	cagcaacagc	tcccactgct	ccccacctcc	540
ccctttgacc	ctcaggatgc	ggcggatat	cgatgccatc	ttaccaaca	gctaccggaa	600
ggtgctggcc	cagctgtccg	cccgaagct	gctccaggac	atcctgaaca	ggcagcaggg	660
agagaggaac	caagagcaag	gagcataatg	actgcaggaa	ttcgatatca	agcttatcgg	720
ggtggcatcc	ctgtgacccc	tccccagtgc	ctctcctggc	cctggaagtt	gccactccag	780
tgcccaccag	ccttgtccta	ataaaattaa	gttgcatacat	tttgtctgac	taggtgtcct	840
tctataatat	tatgggggtg	aggggggtg	tatggagcaa	ggggcaagtt	gggaagacaa	900
cctgtagggc	ctgccccgtc	tattgggaac	caagctggag	tgcagtggca	caatcttggc	960
tcactgcaat	ctccgcctcc	tgggttcaag	cgattctcct	gcctcagcct	cccgagttgt	1020
tgggattcca	ggcatgcatg	accaggctca	gctaattttt	gttttttttg	tagagacggg	1080
gtttcaccat	attggccagg	ctggtctcca	actcctaata	tcaggatgat	taccacctt	1140
ggcctcccaa	attgctggga	ttacaggcgt	gaaccactgc	tccttccct	gtccttctga	1200
ttttaaaata	actataccag	caggaggacg	tccagacaca	gcataggcta	cctggccatg	1260
cccaaccggt	gggacatttg	agttgcttgc	ttggcactgt	cctctcatgc	gttgggtcca	1320
ctcagtagat	gcctgttgaa	ttcgataccg	tcgacctcga	gggggggccc	ggtaccagct	1380
tttgttcctt	ttagtgaggg	ttaatttcga	gcttggcgta	atcatggtca	tagctgtttc	1440
ctgtgtgaaa	ttgttatccg	ctcacaattc	cacacaacat	acgagccgga	agcataaagt	1500
gtaaagcctg	gggtgcctaa	tgagtgaagc	aactcacatt	aattgcgttg	cgctcactgc	1560
ccgctttcca	gtcgggaaac	ctgtcgtgcc	agctgcatta	atgaatcggc	caacgcgcgg	1620
ggagaggcgg	tttgcgatatt	gggcgctctt	ccgcttcttc	gctcactgac	tcgctgcgct	1680
cggtcgttcg	gctgcggcga	gcggtatcag	ctcactcaaa	ggcggtataa	cggttatcca	1740
cagaatcagg	ggataacgca	ggaaagaaca	tgtgagcaaa	aggccagcaa	aaggccagga	1800
accgtaaaaa	ggccgcgttg	ctggcgtttt	tccataggct	ccgccccctt	gacgagcatc	1860
acaaaaatcg	acgctcaagt	cagagggtgg	gaaacccgac	aggactataa	agataccagg	1920
cgtttcccc	tggaaagctc	ctcgtgcgct	ctcctgttcc	gaccctgccg	cttaccggat	1980
acctgtccgc	ctttctccct	tcgggaagcg	tggcgctttc	tcataagctca	cgctgtagggt	2040
atctcagttc	ggtgtagggt	gttcgctcca	agctgggctg	tgtgcacgaa	cccccggttc	2100

```

agcccgaccg ctgcgcctta tccggttaact atcgtcttga gtccaacccg gtaagacacg 2160
acttatcgcc actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg 2220
gtgctacaga gttcttgaag tgggtggccta actacggcta cactagaaga acagtatttg 2280
gtatctgcgc tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg 2340
gcaaacaaac caccgctggg agcgggtggt tttttgtttg caagcagcag attacgcgca 2400
gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagaaga 2460
actcgtcaag aaggcgatag aaggcgatgc gctgcgaatc gggagcggcg ataccgtaaa 2520
gcacgaggaa gcggtcagcc cattcgccgc caagctcttc agcaatatca cgggtagcca 2580
acgctatgtc ctgatagcgg tccgccacac ccagccggcc acagtcgatg aatccagaaa 2640
agcggccatt ttccaccatg atattcggca agcaggcatc gccatgggtc acgacgagat 2700
cctcgccgtc gggcatgcgc gccttgagcc tggcgaacag ttcggtctgc gcgagccct 2760
gatgctcttc gtccagatca tcttgatcga caagaccggc ttccatccga gtacgtgctc 2820
gctcgatgcg atgtttcgct tgggtggtcga atgggcaggt agccggatca agcgtatgca 2880
gccgccgcat tgcacagcc atgatggata ctttctcggc aggagcaagg tgagatgaca 2940
ggagatcctg ccccggcact tcgcccaata gcagccagtc cttcccgtc tcagtgacaa 3000
cgtcgagcac agctgcgcaa ggaacgcccg tcgtggccag ccacgatagc cgcgctgcct 3060
cgtcctgcag ttcattcagg gcaccggaca ggtcggctct gacaaaaaga accgggcgcc 3120
cctgcgctga cagccggaac acggcggcat cagagcagcc gattgtctgt tgtgccagt 3180
catagccgaa tagcctctcc acccaagcgg ccggagaacc tgcgtgcaat ccatcttggt 3240
caatcatgcg aaacgatcct catcctgtct cttgatcaga tcttgatccc ctgcgccatc 3300
agatccttgg cggcaagaaa gccatccagt ttaactttgca gggcttccca accttaccag 3360
agggcgcccc agctggcaat tccggttcgc ttgctgtcca taaaaccgcc cagtctagca 3420
actgttggga agggcgatcg gtgcgggcct cttcgctatt acgccagctg gcgaaagggg 3480
gatgtgctgc aaggcgatta agttgggtaa cgccagggtt ttcccagtca cgac 3534

```

```

<210> 11
<211> 2710
<212> DNA
<213> artificial sequence

```

```

<220>
<223> Vector with a mouse codon optimized GHRH analog sequence

```

```

<400> 11
tgtaatacga ctcaactatag ggcaattgg agctccaccg cgggtggcggc cgtccgcctt 60

```

cggcaccatc	ctcacgacac	ccaaatatgg	cgacgggtga	ggaatggtgg	ggagttat	120
ttagagcggg	gaggaagggt	ggcaggcagc	aggtgttggc	gctctaaaaa	taactcccgg	180
gagttat	tagagcggag	gaatggtgga	cacccaaata	tggcgacggg	tcctcaccgg	240
tcgccatatt	tgggtgtccg	ccctcggccg	gggccgcatt	cctggggggc	gggcgggtgct	300
cccggccggc	tcgataaaag	gctccggggc	cggcggcgcc	ccacgagcta	cccggaggag	360
cgggaggcgc	caagcggatc	ccaaggccca	actccccgaa	ccactcaggg	tcctgtggac	420
agctcaccta	gctgccatgg	tgctctgggt	gctctttgtg	atcctcatcc	tcaccagcgg	480
cagccactgc	agcctgcctc	ccagccctcc	cttcaggatg	cagaggcacg	tggacgccat	540
cttcaccacc	aactacagga	agctgctgag	ccagctgtac	gccaggaagg	tgatccagga	600
catcatgaac	aagcagggcg	agaggatcca	ggagcagagg	gccagggtga	gctgataagc	660
ttatcggggg	ggcatccctg	tgacccctcc	ccagtgcctc	tcctggccct	ggaagttgcc	720
actccagtgc	ccaccagcct	tgtcctaata	aaattaagtt	gcatcat	gtctgactag	780
gtgtccttct	ataatattat	gggggtggagg	gggggtggtat	ggagcaaggg	gcaagttggg	840
aagacaacct	gtagggtctg	agggggggcc	cgggtaccagc	ttttgttccc	tttagtgagg	900
gttaatttcg	agcttgggtct	tccgcttcct	cgctcactga	ctcgctgcgc	tcggtcgttc	960
ggctgcggcg	agcggtatca	gctcactcaa	aggcggtaat	acggttatcc	acagaatcag	1020
gggataacgc	aggaaagaac	atgtgagcaa	aaggccagca	aaaggccagg	aaccgtaaaa	1080
aggccgcgtt	gctggcgttt	ttccataggc	tccgcccccc	tgacgagcat	cacaaaaatc	1140
gacgtcaag	tcagagggtg	cgaaaccgga	caggactata	aagataccag	gcgtttcccc	1200
ctggaagctc	cctcgtgcgc	tctcctgttc	cgaccctgcc	gcttaccgga	tacctgtccg	1260
cctttctccc	ttcgggaagc	gtggcgcttt	ctcatagctc	acgctgtagg	tatctcagtt	1320
cgggtgtaggt	cgttcgtctc	aagctgggct	gtgtgcacga	acccccggt	cagcccgacc	1380
gctgcgcctt	atccggtaac	tatcgtcttg	agtccaaccc	ggtaagacac	gacttatcgc	1440
cactggcagc	agccactggg	aacaggatta	gcagagcgag	gtatgtaggc	ggtgctacag	1500
agttcttgaa	gtgggtggcct	aactacggct	acactagaag	aacagtat	ggatatctgcg	1560
ctctgctgaa	gccagttacc	ttcggaaaaa	gagttggtag	ctcttgatcc	ggcaaacaaa	1620
ccaccgctgg	tagcgggtgg	ttttttgttt	gcaagcagca	gattacgcgc	agaaaaaaag	1680
gatctcaaga	agatcctttg	atcttttcta	cggggctagc	gcttagaaga	actcatccag	1740
cagacggtag	aatgcaatac	gttgagagtc	tggagctgca	ataccataca	gaaccaggaa	1800
acggtcagcc	cattcaccac	ccagttcctc	tgcaatgtca	cgggtagcca	gtgcaatgtc	1860

ctggtaacgg tctgcaacac ccagacgacc acagtcaatg aaaccagaga aacgaccatt	1920
ctcaaccatg atgttcggca ggcattgcac accatgagta actaccaggt cctcaccatc	1980
cggcatacga gctttcagac gtgcaaacag ttcagccggg gccagaccct gatgttcctc	2040
atccagggtca tcctgggtcaa ccagacctgc ttccatacgg gtacgagcac gttcaatacg	2100
atgttttgcc tgggtgggtcaa acggacaggt agctgggtcc aggggtgtgca gacgacgcat	2160
tgcattcagcc atgatagaaa ctttctctgc cggagccagg tgagaagaca gcaggctcctg	2220
acccggaact tcaccagca gcagccagtc acgaccagct tcagtaacta catccagaac	2280
tgcagcacac ggaacaccag tgggtgccag ccaagacaga cgagctgctt catcctgcag	2340
ttcattcaga gcaccagaca ggtcagtttt aacaaacaga actggacgac cctgtgcaga	2400
cagacggaaa acagctgcat cagagcaacc aatgggtctgc tgtgcccagt cataaccaa	2460
cagacgttca acccaggctg ccggagaacc tgcattgcaga ccattcctgtt caatcatgcg	2520
aaacgatcct catcctgtct cttgatcaga tcttgatccc ctgcgccatc agatccttgg	2580
cggcaagaaa gccatccagt ttactttgca gggtctccca acctaccag agggcgcccc	2640
agctggcaat tccggttcgc ttgctgtcca taaaaccgcc cagtctagca actgttggga	2700
agggcgatcg	2710

<210> 12

<211> 2713

<212> DNA

<213> artificial sequence

<220>

<223> Vector with a rat codon optimized GHRH analog sequence

<400> 12

tgtatacga ctactatag ggcgaattgg agtccaccg cggtagcggc cgtccgccct	60
cggcaccatc ctacgacac ccaaatatgg cgacgggtga ggaatgggtg ggagttat	120
ttagagcggg gaggaagggt ggcaggcagc aggtgttggc gctctaaaaa taactccc	180
gagttat	240
tcgccatatt tgggtgtccg ccctcggccg gggccgcatt cctgggggcc gggcgggtgct	300
cccgccgcc tcgataaaag gctccggggc cggcggcgcc ccacgagcta cccggaggag	360
cgggagggcg caagcggatc ccaaggccca actccccgaa ccactcaggg tcctgtggac	420
agctcaccta gctgccatgg ccctgtgggt gttcttcgtg ctgctgaccc tgaccagcgg	480
aagccactgc agcctgcctc ccagccctcc cttcaggggt cgcgggcacg ccgacgccat	540
cttcaccagc agctacagga ggatcctggg ccagctgtac gctaggaagc tcctgcacga	600

gatcatgaac aggcagcagg gcgagaggaa ccaggagcag aggagcaggt tcaactgata	660
agcttatcgg ggtggcatcc ctgtgacccc tcccagtgcc ctctcctggc cctggaagtt	720
gccactccag tgcccaccag ccttgccta ataaaattaa gttgcatcat tttgtctgac	780
taggtgtcct tctataatat tatgggggtgg aggggggtgg tatggagcaa ggggcaagtt	840
gggaagacaa cctgtagggc tcgagggggg gcccggtacc agcttttggt ccctttagtg	900
agggttaatt tcgagcttgg tcttcgcgtt cctcgctcac tgactcgctg cgctcggtcg	960
ttcggctgcg gcgagcggta tcagctcact caaaggcggg aatacgggta tccacagaat	1020
caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta	1080
aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag catcacaaaa	1140
atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc	1200
cccctggaag ctccctcggt cgctctcctg ttccgacct gccgcttacc ggatacctgt	1260
ccgcctttct cccttcggga agcgtggcg tttctcatag ctacgctgt aggtatctca	1320
gttcgggtga ggtcgttcgc tccaagctgg gctgtgtgca cgaaccccc gttcagccc	1380
accgctgctc cttatccggt aactatcgtc ttgagtcaa cccgtaaga cacgacttat	1440
cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta	1500
cagagttctt gaagtgggtg cctaactacg gctacactag aagaacagta tttggtatct	1560
gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac	1620
aaaccaccgc tggtagcggg ggtttttttg tttgcaagca gcagattacg cgcagaaaaa	1680
aaggatctca agaagatcct ttgatctttt ctacggggct agcgcttaga agaactcatc	1740
cagcagacgg tagaatgcaa tacgttgaga gtctggagct gcaataccat acagaaccag	1800
gaaacgggtc gccattcac caccagttc ctctgcaatg tcacgggtag ccagtgcaat	1860
gtcctggtaa cggctctgcaa caccagacg accacagtca atgaaaccag agaaacgacc	1920
attctcaacc atgatgttcg gcaggcatgc atcaccatga gtaactacca ggtcctcacc	1980
atccggcata cgagctttca gacgtgcaaa cagttcagcc ggtgccagac cctgatgttc	2040
ctcatccagg tcatcctggt caaccagacc tgcttcata cgggtacgag cacgttcaat	2100
acgatgtttt gcctgggtgt caaacggaca ggtagctggg tccagggtgt gcagacgacg	2160
cattgcatca gccatgatag aaactttctc tgccggagcc aggtgagaag acagcaggtc	2220
ctgacctgga acttcacca gcagcagcca gtcacgacca gcttcagtaa ctacatccag	2280
aactgcagca cacggaacac cagtgggtgc cagccaagac agacgagctg cttcatcctg	2340
cagttcattc agagcaccag acaggtcagt ttaacaaaac agaactggac gaccctgtgc	2400

agacagacgg	aaaacagctg	catcagagca	accaatggtc	tgctgtgcc	agtcataacc	2460
aaacagacgt	tcaaccagg	ctgccggaga	acctgcatgc	agaccatcct	gttcaatcat	2520
gcgaaacgat	cctcatcctg	tctcttgatc	agatcttgat	cccctgcgcc	atcagatcct	2580
tggcggcaag	aaagccatcc	agtttacttt	gcagggcttc	ccaaccttac	cagagggcgc	2640
cccagctggc	aattccgggt	cgcttgctgt	ccataaaacc	gccagtccta	gcaactgttg	2700
ggaagggcga	tcg					2713

<210> 13
 <211> 2704
 <212> DNA
 <213> artificial sequence

<220>
 <223> Vector with a bovine codon optimized GHRH analog sequence

<400> 13	
tgtaatacga	ctcactatag ggcgaattgg agctccaccg cggcggcggc cgtccgccct 60
cggcaccatc	ctcacgacac ccaaatatgg cgacgggtga ggaatgggtg ggagttattt 120
ttagagcggg	gaggaagggtg ggcaggcagc aggtgttggc gctctaaaaa taactcccgg 180
gagttatttt	tagagcggag gaatgggtga caccctaaata tggcgacggg tcctcaccgg 240
tcgccatatt	tgggtgtccg ccctcggccg gggccgcatt cctggggggc gggcgggtgt 300
cccgcggcc	tcgataaaag gctccggggc cggcggcggc ccacgagcta cccggaggag 360
cgggagggcg	caagcggatc ccaaggccca actccccgaa cactcaggg tcctgtggac 420
agctcaccta	gctgccatgg tgctgtgggt gttcttctctg gtgaccctga ccctgagcag 480
cggctcccac	ggctccctgc cctcccagcc tctgcgcac cctcgctacg ccgacgccat 540
cttcaccaac	agctaccgca aggtgctcgg ccagctcagc gcccgcaagc tcctgcagga 600
catcatgaac	cggcagcagg gcgagcgcaa ccaggagcag ggagcctgat aagcttatcg 660
gggtggcatc	cctgtgacct ctccccagtg cctctcctgg ccctggaagt tgccactcca 720
gtgcccacca	gccttgtcct aataaaatta agttgcatca ttttgtctga ctagggtgtcc 780
ttctataata	ttatgggggtg gaggggggtg gtatggagca aggggcaagt tgggaagaca 840
acctgtaggg	ctcgaggggg ggcccgttac cagcttttgt tccctttagt gaggggttaat 900
ttcgagcttg	gtcttccgct tcctcgctca ctgactcgct gcgctcggtc gttcggctgc 960
ggcgagcggg	atcagctcac tcaaaggcgg taatacgggt atccacagaa tcaggggata 1020
acgcaggaaa	gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg 1080
cgttgctggc	gtttttccat aggtcccgcc ccctgacga gcatcacaaa aatcgacgct 1140

caagtcagag	gtggcgaaac	ccgacaggac	tataaagata	ccaggcgttt	ccccctggaa	1200
gctccctcgt	gcgctctcct	gttccgaccc	tgccgcttac	cggatacctg	tccgcctttc	1260
tcccttcggg	aagcgtggcg	ctttctcata	gtcacgctg	taggtatctc	agttcgggtg	1320
aggtcgttcg	ctccaagctg	ggctgtgtgc	acgaaccccc	cggtcagccc	gaccgctgcg	1380
ccttatccgg	taactatcgt	cttgagtcca	acccggtaag	acacgactta	tcgccactgg	1440
cagcagccac	tggtaacagg	attagcagag	cgaggatatgt	aggcggtgct	acagagttct	1500
tgaagtggtg	gcctaactac	ggctacacta	gaagaacagt	atgttggtatc	tgcgctctgc	1560
tgaagccagt	taccttcgga	aaaagagttg	gtagctcttg	atccggcaaa	caaaccaccg	1620
ctggtagcgg	tggttttttt	gtttgcaagc	agcagattac	gcgcagaaaa	aaaggatctc	1680
aagaagatcc	tttgcattct	tctacggggc	tagcgcttag	aagaactcat	ccagcagacg	1740
gtagaatgca	atacgttgag	agtctggagc	tgcaatacca	tacagaacca	ggaaacggtc	1800
agcccatcca	ccaccaggtt	cctctgcaat	gtcacgggta	gccagtgcaa	tgtcctggta	1860
acggctctgca	acaccagac	gaccacagtc	aatgaaacca	gagaaacgac	cattctcaac	1920
catgatgttc	ggcaggcatg	catcaccatg	agtaactacc	aggtcctcac	catccggcat	1980
acgagctttc	agacgtgcaa	acagttcagc	cgggtgccaga	ccctgatgtt	cctcatccag	2040
gtcatcctgg	tcaaccagac	ctgcttccat	acgggtacga	gcacgttcaa	tacgatgttt	2100
tgcttggtgg	tcaaacggac	aggtagctgg	gtccagggtg	tgcacgagac	gcattgcatc	2160
agccatgata	gaaactttct	ctgccggagc	caggtgagaa	gacagcaggt	cctgaccggg	2220
aacttcaccc	agcagcagcc	agtcacgacc	agcttcagta	actacatcca	gaactgcagc	2280
acacggaaca	ccagtgggtg	ccagccaaga	cagacgagct	gcttcatcct	gcagttcatt	2340
cagagcacca	gacaggctag	ttttaacaaa	cagaactgga	cgaccctgtg	cagacagacg	2400
gaaaacagct	gcatcagagc	aaccaatggt	ctgctgtgcc	cagtcataac	caaacagacg	2460
ttcaaccagg	gctgccggag	aacctgcatg	cagaccatcc	tgttcaatca	tgcgaaacga	2520
tcctcatcct	gtctcttgat	cagatcttga	tccccctgcg	catcagatcc	ttggcgggcaa	2580
gaaagccatc	cagtttactt	tgcagggtct	cccaacctta	ccagagggcg	ccccagctgg	2640
caattccggt	tcgcttgctg	tccataaaac	cgcccagctc	agcaactgtt	gggaagggcg	2700
atcg						2704

<210> 14
 <211> 2704
 <212> DNA
 <213> artificial sequence

<220>

<223> Vector with a ovine codon optimized GHRH analog sequence

<400> 14

tgtaatacga ctcactatag ggcgaattgg agctccaccg cgggtggcggc cgtccgcctt	60
cggcaccatc ctcacgacac ccaaatatgg cgacgggtga ggaatggtgg ggagttattt	120
ttagagcggg gaggaagggt ggcaggcagc aggtgttggc gctctaaaaa taactcccgg	180
gagttatttt tagagcggag gaatggtgga cacccaaata tggcgacggg tctcaccgg	240
tcgccatatt tgggtgtccg ccctcggccg gggccgcatt cctggggggc gggcgggtgct	300
cccgcccggc tcgataaaaag gctccggggc cggcggcggc ccacgagcta cccggaggag	360
cgggaggcgc caagcggatc ccaaggccca actccccgaa ccactcaggg tctgtggac	420
agctcaccta gctgccatgg tgctgtgggt gttcttcttg gtgaccctga ccctgagcag	480
cggaagccac ggcagcctgc ccagccagcc cctgaggatc cctaggtacg ccgacgcat	540
cttcaccaac agctacagga agatcctggg ccagctgagc gctaggaagc tctgcagga	600
catcatgaac aggcagcagg gcgagaggaa ccaggagcag ggcgcctgat aagcttatcg	660
gggtggcatc cctgtgacct ctccccagtg cctctcctgg ccctggaagt tgccactcca	720
gtgcccacca gccttgtcct aataaaatta agttgcatca ttttgtctga ctagggtgtcc	780
ttctataata ttatgggggtg gaggggggtg gtatggagca aggggcaagt tgggaagaca	840
acctgtaggg ctcgaggggg ggcccgttac cagcttttgt tccctttagt gagggttaat	900
ttcgagcttg gtcttccgct tctcgtccta ctgactcgct gcgctcggtc gttcggctgc	960
ggcgagcggg atcagctcac tcaaaggcgg taatacgggt atccacagaa tcaggggata	1020
acgcaggaaa gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg	1080
cgttgctggc gtttttccat aggtcccgcc cccctgacga gcatcacaaa aatcgacgct	1140
caagtcagag gtggcgaaac ccgacaggac tataaagata ccaggcggtt cccctggaa	1200
gctccctcgt gcgctctcct gttccgacct tgccgcttac cggataacct tccgcctttc	1260
tcccttcggg aagcgtggcg ctttctcata gctcacgctg taggtatctc agttcgggtg	1320
aggtcgttcg ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg	1380
ccttatccgg taactatcgt cttgagtcca acccggttaag acacgactta tcgccactgg	1440
cagcagccac tggtaacagg attagcagag cgaggatatgt aggcgggtgct acagagttct	1500
tgaagtgggt gcctaactac ggctacacta gaagaacagt atttggtatc tgcgctctgc	1560
tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg	1620
ctggtagcgg tgggtttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc	1680

aagaagatcc tttgatcttt tctacggggc tagcgcttag aagaactcat ccagcagacg	1740
gtagaatgca atacgttgag agtctggagc tgcaatacca tacagaacca ggaaacggtc	1800
agcccattca ccaccagtt cctctgcaat gtcaagggtg gccagtgcaa tgtcctggta	1860
acggctctgca acaccagac gaccacagtc aatgaaacca gagaaacgac cattctcaac	1920
catgatgttc ggcaggcatg catcaccatg agtaactacc aggtcctcac catccggcat	1980
acgagctttc agacgtgcaa acagttcagc cgggtgccaga ccctgatgtt cctcatccag	2040
gtcatcctgg tcaaccagac ctgcttccat acgggtacga gcacgttcaa tacgatgttt	2100
tgcctggtgg tcaaacggac aggtagctgg gtccagggtg tgcagacgac gcattgcac	2160
agccatgata gaaactttct ctgccggagc caggtgagaa gacagcaggt cctgacccgg	2220
aacttcaccc agcagcagcc agtcacgacc agcttcagta actacatcca gaactgcagc	2280
acacggaaca ccagtgggtg ccagccaaga cagacgagct gcttcacctt gcagttcatt	2340
cagagcacca gacaggtcag ttttaacaaa cagaactgga cgaccctgtg cagacagacg	2400
gaaaacagct gcatcagagc aaccaatggt ctgctgtgcc cagtcataac caaacagacg	2460
ttcaaccag gctgccggag aacctgcatg cagaccatcc tgttcaatca tgcgaaacga	2520
tcctcatcct gtctcttgat cagatcttga tcccctgcgc catcagatcc ttggcggcaa	2580
gaaagccatc cagtttactt tgcagggtt cccaacctta ccagagggcg cccagctgg	2640
caattccggt tcgcttgctg tccataaaac cgcccagtct agcaactgtt gggaagggcg	2700
atcg	2704

<210> 15
 <211> 2713
 <212> DNA
 <213> artificial sequence

<220>
 <223> Vector with a chicken codon optimized GHRH analog sequence

<400> 15	
tgtaatacga ctcaactatag ggcgaattgg agctccaccg cggtaggcggc cgtccgcctt	60
cggcaccatc ctcaacgacac ccaaatatgg cgacgggtga ggaatggtgg ggagttatct	120
ttagagcggg gaggaagggtg ggcaggcagc aggtgttggc gctctaaaaa taactcccgg	180
gagttatctt tagagcggag gaatggtgga caccctaaata tggcgacggg tcctcaccgg	240
tcgccatatt tgggtgtccg ccctcggccg gggccgcatt cctggggggc gggcgggtgt	300
cccggccgcc tcgataaaag gctccggggc cggcggcgcc ccacgagcta cccggaggag	360
cgggagggcg caagcggatc ccaaggccca actccccgaa cactcaggg tcctgtggac	420

agctcaccta gctgccatgg ccctgtgggt gttctttgtg ctgctgaccc tgacctccgg	480
aagccactgc agcctgccac ccagcccacc cttccgcgtc aggcgccacg ccgacggcat	540
cttcagcaag gcctaccgca agctcctggg ccagctgagc gcacgcaact acctgcacag	600
cctgatggcc aagcgcgtgg gcagcggact gggagacgag gccgagcccc tgagctgata	660
agcttatcgg ggtggcatcc ctgtgacccc tccccagtgc ctctcctggc cctggaagtt	720
gccactccag tgcccaccag ccttgtccta ataaaattaa gttgcatcat tttgtctgac	780
taggtgtcct tctataatat tatggggtgg aggggggtgg tatggagcaa ggggcaagtt	840
gggaagacaa cctgtagggc tcgagggggg gcccggtacc agcttttggt ccctttagtg	900
agggttaatt tcgagcttgg tcttccgctt cctcgtcac tgactcgtg cgctcggtcg	960
ttcggctgcg gcgagcggta tcagctcact caaaggcggg aatacgggta tccacagaat	1020
caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta	1080
aaaaggccgc gttgctggcg tttttccata ggctccgcc ccctgacgag catcacaaaa	1140
atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc	1200
cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc ggatacctgt	1260
ccgcctttct cccttcggga agcgtggcgc tttctcatag ctcacgctgt aggtatctca	1320
gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaaccccc gttcagcccc	1380
accgctgcgc cttatccggt aactatcgtc ttgagtcaa cccgtaaga cacgacttat	1440
cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta	1500
cagagtctct gaagtgggtg cctaactacg gctacactag aagaacagta tttggtatct	1560
gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac	1620
aaaccaccgc tggtagcggg ggtttttttg tttgcaagca gcagattacg cgcagaaaaa	1680
aaggatctca agaagatcct ttgatctttt ctacggggct agcgcttaga agaactcatc	1740
cagcagacgg tagaatgcaa tacgttgaga gtctggagct gcaataccat acagaaccag	1800
gaaacggtca gccattcac caccagttc ctctgcaatg tcacgggtag ccagtgcaat	1860
gtcctggtaa cggctctgca caccagacg accacagtca atgaaaccag agaaacgacc	1920
attctcaacc atgatgttcg gcaggcatgc atcaccatga gtaactacca ggtcctcacc	1980
atccggcata cgagctttca gacgtgcaaa cagttcagcc ggtgccagac cctgatgttc	2040
ctcatccagg tcatcctggg caaccagacc tgcttccata cgggtacgag cacgttcaat	2100
acgatgtttt gcctgggtgg caaacggaca ggtagctggg tccaggggtg gcagacgacg	2160
cattgcatca gccatgatag aaactttctc tgccggagcc aggtgagaag acagcaggtc	2220

ctgacccgga acttcaccca gcagcagcca gtcacgacca gcttcagtaa ctacatccag	2280
aactgcagca cacggaacac cagtgggtgc cagccaagac agacgagctg cttcatcctg	2340
cagttcattc agagcaccag acaggtcagt ttttaacaaac agaactggac gaccctgtgc	2400
agacagacgg aaaacagctg catcagagca accaatgggc tgctgtgccc agtcataacc	2460
aaacagacgt tcaaccagg ctgccggaga acctgcatgc agaccatcct gttcaatcat	2520
gcgaaacgat cctcatcctg tctcttgatc agatcttgat cccctgcgcc atcagatcct	2580
tggcggcaag aaagccatcc agtttacttt gcaggggcttc ccaaccttac cagagggcgc	2640
cccagctggc aattccgggt cgcttgctgt ccataaaacc gccagtccta gcaactgttg	2700
ggaagggcga tcg	2713

<210> 16
 <211> 382
 <212> DNA
 <213> artificial sequence

<220>
 <223> This is the synthetic promoter c1-26.

<400> 16	
ggcggccgag ggcggcgggg caggcagcag gtgttggcac cattcctcac cgctctaaaa	60
ataactcccg tgaggaatgg tgccgtcgcc atatttgggt gtcgacaccc aaatatggcg	120
acgggtgagg aatggtgggc aggcagcagg tggtgggaca cccaaatatg gcgacggcca	180
acacctgctg cctgccggga gttattttta gagcggggag ttatttttag agcggtgagg	240
aatggtggac acccaaatat ggcgacggcc ggggccgcac tcctgggggc cgggcgggtgc	300
tcccgcccgc ctcgataaaa ggctccgggg ccggcggcgg cccacgagct acccgaggga	360
gcgggaggcg ccaagctcta ga	382

<210> 17
 <211> 218
 <212> DNA
 <213> artificial sequence

<220>
 <223> This is the synthetic promoter sequence for c2-26.

<400> 17	
cgccgctcgc catatttggg tgtccgtctt aaaaataact cccgacaccc aaatatggcg	60
acggggcagg cagcaggtgt tgggacaccc aaatatggcg acggccgggg ccgcattcct	120
gggggcccgg cggtgctccc gcccgctcgc ataaaaggct ccggggcccg cggcgcccca	180
cgagctaccc ggaggagcgg gaggcgcaa gctctaga	218

<210> 18
 <211> 230
 <212> DNA
 <213> artificial sequence

<220>
 <223> This is the synthetic sequence for c2-27.

<400> 18
 cggccgtcgc catatttggg tgtcggcagg cagcaggtgt tggcaccatt cctcaccctg 60
 cgccatattt ggggtgtcggc aggcagcagt gttgggacac ccaaatatgg cgacggccgg 120
 ggccgcattc ctggggggccg ggcggtgctc ccgcccgcct cgataaaaagg ctccggggcc 180
 ggcggcgggc cagcagctac ccggaggagc gggaggcgcc aagctctaga 230

<210> 19
 <211> 231
 <212> DNA
 <213> artificial sequence

<220>
 <223> This is the synthetic promoter for c5-5.

<400> 19
 cggccgtccg ccctcgggac acccaaatat ggcgacgggt gaggaatggt gcaccattcc 60
 tcacgggagt tatttttaga gcggtgagga atggtggaca ccaaatatg gcgacggccg 120
 gggccgcatt cctggggggcc gggcggtgct ccgcccgcct tcgataaaaag gctccggggc 180
 cggcggcggc ccacgagcta cccggaggag cgggaggcgc caagctctag a 231

<210> 20
 <211> 255
 <212> DNA
 <213> artificial sequence

<220>
 <223> This is the synthetic promoter for c6-5.

<400> 20
 cggccgtcgc catatttggg tgtcccaaca cctgctgcct gcccgtcgc catatttggg 60
 gtcggcaggc agcaggtggt ggccaacacc tgctgcctgc cgggagttat ttttagagcg 120
 gacacccaaa tatggcgacg gccggggccg cattcctggg ggccgggagg tgctcccggc 180
 cgcctcgata aaaggctccg gggccggcgg cggcccacga gctaccggga ggagcgggag 240
 gcgccaagct ctaga 255

<210> 21
 <211> 283

<212> DNA
 <213> artificial sequence

 <220>
 <223> This is the synthetic promoter for c6-16.

 <400> 21
 cggccgtcgc catatttggg tgtccgctct aaaaataact cccccaacac ctgctgcctg 60
 ccccgctgcc atatttgggt gtcggcaggc agcagggtgtt ggccaacacc tgctgcctgc 120
 cccaacacct gctgcctgcc ccgtcgccat atttggtgtc cgccctcggc cggggccgca 180
 ttctctggggg ccggggcggg ctcccgcccg cctcgataaa aggctccggg gccggcggcg 240
 gccacgagc taccggagg agcgggagg gccaaagtct aga 283

 <210> 22
 <211> 263
 <212> DNA
 <213> artificial sequence

 <220>
 <223> This is the synthetic promoter for c6-39.

 <400> 22
 cggccgtccg ccctcggggg agttattttt agagcgccaa cacctgctgc ctgccccgtc 60
 gccatatttg ggtgtcggca ggcagcagg gttgggggag ttatttttag agcgccgtcg 120
 ccatatttgg gtgtcccag ggcggacggc cggggccgca ttctctggggg ccggggcggg 180
 ctcccgcccg cctcgataaa aggctccggg gccggcggcg gccacgagc taccggagg 240
 agcgggagg gccaaagtct aga 263

 <210> 23
 <211> 10
 <212> DNA
 <213> artificial sequence

 <220>
 <223> Proximal SRE - skeletal a-actin

 <220>
 <221> MISC_FEATURE
 <222> (3)..(3)
 <223> n at position 3 may be adenine or thymine

 <220>
 <221> MISC_FEATURE
 <222> (4)..(4)
 <223> n at position 4 may be adenine or thymine

 <220>
 <221> MISC_FEATURE
 <222> (5)..(5)

<223> n at position 5 may be adenine or thymine

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> n at position 6 may be adenine or thymine

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> n at position 7 may be adenine or thymine

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> n at position 8 may be adenine or thymine

<400> 23

ccnnnnnnngg

10

<210> 24

<211> 14

<212> DNA

<213> artificial sequence

<220>

<223> MEF-2 site, skeletal a-actin promoter

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> n at position 1 may be cytosine or thymine

<220>

<221> MISC_FEATURE

<222> (12)..(12)

<223> n at position 12 may be cytosine or thymine

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> n at position 13 may be cytosine or thymine

<220>

<221> MISC_FEATURE

<222> (14)..(14)

<223> n at position 14 may be cytosine or thymine

<400> 24

ntaaaaataa cnnn

14

<210> 25

<211> 14

<212> DNA

<213> artificial sequence

<220>

<223> Sp1 element

<400> 25

ccgtccgcc tcgg

14

EXHIBIT A



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
10/699,597	10/30/2003	Ruxandra Draghia-Akli	108328.00161 (AVSI-0027)

CONFIRMATION NO. 7762

ABANDONMENT/TERMINATION
LETTER

25555
 JACKSON WALKER LLP
 901 MAIN STREET
 SUITE 6000
 DALLAS, TX 75202-3797

Date Mailed: 03/14/2007

NOTICE OF ABANDONMENT UNDER 37 CFR 1.53 (f) OR (g)

The above-identified application is abandoned for failure to timely or properly reply to the Notice to File Missing Parts (Notice) mailed on 07/06/2006.

- No reply was received.

If a complete reply to the notice was previously filed by applicant within the time period set forth in the notice, applicant may request for reconsideration of the holding of abandonment within 2 months from the mailing of this notice of abandonment by filing a petition to withdraw the holding of abandonment under 37 CFR 1.181(a). No petition fee is required. The petition must be accompanied by a true copy of the originally filed reply and the item (s) identified in one of the following:

1. A properly itemized date-stamped postcard receipt (see MPEP § 503);
2. If the originally filed reply included a certificate of mailing or transmission in compliance with 37 CFR 1.8(a), a copy of the certificate of mailing or transmission and a statement in compliance with 37 CFR 1.8(b) (see MPEP § 512); or
3. If the reply was filed via Express Mail, a submission satisfying the requirements of 37 CFR 1.10(e) including, for example, a copy of the Express Mail mailing label showing the "date-in" (see MPEP § 513).

Any petition to withdraw the holding of abandonment should be directed to OIPE.

If applicant did not previously file a complete reply within the time period set forth in the notice, applicant may file a petition to revive the application under 37 CFR 1.137.

Under 37 CFR 1.137(a), a petition requesting the application be revived on the grounds of **UNAVOIDABLE DELAY** must be filed promptly after the applicant becomes aware of the abandonment and such petition must be accompanied by: (1) an adequate showing of the cause of unavoidable delay; (2) the required reply to the above-identified Notice; (3) the petition fee set forth in 37 CFR 1.17(l); and (4) a terminal disclaimer if required by 37 CFR 1.137(d). See MPEP § 711.03(c) and Form PTO/SB/61.

Under 37 CFR 1.137(b), a petition requesting the application be revived on the grounds of **UNINTENTIONAL DELAY** must be filed promptly after applicant becomes aware of the abandonment and such petition must be accompanied by: (1) a statement that the entire delay was unintentional; (2) the required reply to the above-

MAR 16 2007

identified Notice; (3) the petition fee set forth in 37 CFR 1.17(m); and (4) a terminal disclaimer if required by 37 CFR 1.137(d). See MPEP § 711.03(c) and Form PTO/SB/64.

Any questions concerning petitions to revive should be directed to the "Office of Petitions" at (571) 272-3282.

*A copy of this notice **MUST** be returned with the reply.*

Tequest Woldeyes
Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199
PART 1 - ATTORNEY/APPLICANT COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
10/699,597	10/30/2003	Ruxandra Draghia-Akli	108328.00161 (AVSI-0027)

CONFIRMATION NO. 7762

**ABANDONMENT/TERMINATION
 LETTER**

25555
 JACKSON WALKER LLP
 901 MAIN STREET
 SUITE 6000
 DALLAS, TX 75202-3797

Date Mailed: 03/14/2007

NOTICE OF ABANDONMENT UNDER 37 CFR 1.53 (f) OR (g)

The above-identified application is abandoned for failure to timely or properly reply to the Notice to File Missing Parts (Notice) mailed on 07/06/2006.

- No reply was received.

If a complete reply to the notice was previously filed by applicant within the time period set forth in the notice, applicant may request for reconsideration of the holding of abandonment within 2 months from the mailing of this notice of abandonment by filing a petition to withdraw the holding of abandonment under 37 CFR 1.181(a). No petition fee is required. The petition must be accompanied by a true copy of the originally filed reply and the item (s) identified in one of the following:

1. A properly itemized date-stamped postcard receipt (see MPEP § 503);
2. If the originally filed reply included a certificate of mailing or transmission in compliance with 37 CFR 1.8(a), a copy of the certificate of mailing or transmission and a statement in compliance with 37 CFR 1.8(b) (see MPEP § 512); or
3. If the reply was filed via Express Mail, a submission satisfying the requirements of 37 CFR 1.10(e) including, for example, a copy of the Express Mail mailing label showing the "date-in" (see MPEP § 513).

Any petition to withdraw the holding of abandonment should be directed to OIPE.

If applicant did not previously file a complete reply within the time period set forth in the notice, applicant may file a petition to revive the application under 37 CFR 1.137.

Under 37 CFR 1.137(a), a petition requesting the application be revived on the grounds of **UNAVOIDABLE DELAY** must be filed promptly after the applicant becomes aware of the abandonment and such petition must be accompanied by: (1) an adequate showing of the cause of unavoidable delay; (2) the required reply to the above-identified Notice; (3) the petition fee set forth in 37 CFR 1.17(l); and (4) a terminal disclaimer if required by 37 CFR 1.137(d). See MPEP § 711.03(c) and Form PTO/SB/61.

Under 37 CFR 1.137(b), a petition requesting the application be revived on the grounds of **UNINTENTIONAL DELAY** must be filed promptly after applicant becomes aware of the abandonment and such petition must be accompanied by: (1) a statement that the entire delay was unintentional; (2) the required reply to the above-

identified Notice; (3) the petition fee set forth in 37 CFR 1.17(m); and (4) a terminal disclaimer if required by 37 CFR 1.137(d). See MPEP § 711.03(c) and Form PTO/SB/64.

Any questions concerning petitions to revive should be directed to the "Office of Petitions" at (571) 272-3282.

*A copy of this notice **MUST** be returned with the reply.*

Request Woldes

Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199

PART 2 - COPY TO BE RETURNED WITH RESPONSE



1 Notice of Abandonment

This application is abandoned in view of applicant's failure to timely file a proper reply to the Office notice mailed 07/06/06

Petition to Withdraw the Holding of Abandonment

If a complete reply to the notice was previously filed by applicant within the time period set forth in the notice, applicant may request for reconsideration of the holding of abandonment within **2 months** from the mailing of this notice of abandonment by filing a petition to withdraw the holding of abandonment under 37 CFR 1.181(a). No petition fee is required. The petition must be accompanied by a true copy of the originally filed reply and the item(s) identified in one of the following:

1. A properly itemized date-stamped postcard receipt (see MPEP § 503);
2. If the originally filed reply included a certificate of mailing or transmission in compliance with 37 CFR 1.8(a), a copy of the certificate of mailing or transmission and a statement in compliance with 37 CFR 1.8(b) (see MPEP § 512); or
3. If the reply was filed via Express Mail, a submission satisfying the requirements of 37 CFR 1.10(e) including, for example, a copy of the Express Mail mailing label showing the "date-in" (see MPEP § 513).

Any petition to withdraw the holding of abandonment should be transmitted by facsimile directly to OIPE Customer Service at (703) 308-7751.

Petition to Revive an Abandoned Application

If applicant did not previously file a complete reply within the time period set forth in the notice, applicant may file a petition to revive the application under 37 CFR 1.137.

Under 37 CFR 1.137(a), a petition requesting the application be revived on the grounds of UNAVOIDABLE DELAY must be filed promptly after the applicant becomes aware of the abandonment and such petition must be accompanied by:

1. an adequate showing of the cause of unavoidable delay;
2. the required reply to the above-identified notice;
3. the petition fee set forth in 37 CFR 1.17(i); and
4. a terminal disclaimer if required by 37 CFR 1.137(d).

See MPEP § 711.03(c) and Form PTO/SB/61.

Under 37 CFR 1.137(b), a petition requesting the application be revived on the grounds of UNINTENTIONAL DELAY must be filed promptly after applicant becomes aware of the abandonment and such petition must be accompanied by:

1. a statement that the entire delay was unintentional;
2. the required reply to the above-identified notice;
3. the petition fee set forth in 37 CFR 1.17(m); and
4. a terminal disclaimer if required by 37 CFR 1.137(d).

See MPEP § 711.03(c) and Form PTO/SB/64.

Any questions concerning petitions to revive should be directed to Office of Petitions at (703) 305-9282.

Any questions regarding this notice should be directed to OIPE Customer Service at (703) 308-1202.

EXHIBIT B



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371(c) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
10/699,597	10/30/2003	Ruxandra Draghia-Akli	108328.00161 (AVSI-0027)

CONFIRMATION NO. 7762
 WITHDRAWAL
 NOTICE

JACKSON WALKER LLP
 901 MAIN STREET
 SUITE 6000
 DALLAS, TX 75202-3797

Date Mailed: 07/06/2006

WITHDRAWAL OF PREVIOUSLY SENT NOTICE

The Notice mailed on 06/01/2004 was sent in error and is hereby withdrawn. A corrected Notice is enclosed. The time period for reply runs from the mail date of the corrected Notice. The Office regrets any inconvenience the error may have caused.

A copy of this notice MUST be returned with the reply.

Customer Service Center
 Initial Patent Examination Division (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382
 PART 3 - OFFICE COPY



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/699,597	10/30/2003	Ruxandra Draghia-Akli	108328.00161 (AVSI-0027)

25555
JACKSON WALKER LLP
901 MAIN STREET
SUITE 6000
DALLAS, TX 75202-3797

CONFIRMATION NO. 7762
FORMALITIES
LETTER

Date Mailed: 07/06/2006

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Filing Date Granted

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR §§ 1.821-1.825. The application must be in sequence compliance before examination on the merits.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

See the attachment.

Applicant Must Provide as part of the response:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).


To Download PatentIn Software, visit <http://www.uspto.gov/web/patents/software.htm>

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For PatentIn Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for PatentIn Software Program Help @ ebc@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.


Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199, or 1-800-972-6382
PART 3 - OFFICE COPY

OIPE ROUTING SHEET

APPLICATION



IFW DocCode - SEQREQ

Index using Current Date

10699597

TO BE DELIVERED TO:

Tech Center Scanning

Sequence Rule Compliance Review Item

<input type="checkbox"/>	CRF, paper copy of sequence listing, and statement that both are same missing
<input type="checkbox"/>	CRF contains error(s) according to STIC Report
<input type="checkbox"/>	CRF damaged or unreadable according to STIC Report
<input type="checkbox"/>	CRF transferred from prior application is not compliant

Place an "X" in the appropriate box

DAVE TRONG NGUYEN
SUPERVISORY PATENT EXAMINER

Comment Sheet

APPLICATION SERIAL NUMBER

10/699597

**DOES NOT COMPLY WITH THE
SEQUENCE RULES. See reasons below.**

Page(s) 4, line 3 and 12 and page 18, line 17 contain sequences not found in the CRF.

EXHIBIT C

JW# 108328.0161

PRINTED ON: 4/10/2007

COUNTRY	US	UNITED STATES	TITLE		PRIOR	11/4/2002	
NEW/CON	FCA	SERIAL#	10/699,597	(AVSI-0027) SYNTHETIC MUSCLE PROMOTERS WITH ACTIVITIES EXCEEDING NATURALLY OCCURRING REGULATORY SEQUENCES IN CARDIAC CELLS	MAIL	10/30/2003	
RELATED	108328.0085	PATENT#			FILE	10/30/2003	
TYPE	UTL	STATUS	PENDING		PUBL		
CLIENT	108328	ADVISYS, Inc.	1		ISSUE		
AGENT				CREF		1ST	10/30/2003
				AREF		EXP	10/30/2023

ID	O	ACTION	BASE	DUE IN	DUE	EXTNS	FINAL	EXT	RESPONSE	CALL UP	1	2	P
FO	N	FOREIGN FILING DUE	11/4/2002	12M	11/4/2003		11/4/2003	0	10/30/2003	3M	Y	Y	Y
PC	N	POST CARD CHECK	10/30/2003	1M	11/30/2003		11/30/2003	0	11/17/2003	0M	Y	Y	Y
DS	N	INF DISCLOSURE STMT	10/30/2003	3M	1/30/2004		1/30/2004	0	2/11/2004	1M	Y	Y	Y
FS	N	SC-FILING RECEIPT	10/30/2003	3M	1/30/2004		1/30/2004	0	2/9/2004	0M	Y	Y	Y
G2	N	MISSING PARTS (2 MO)	2/6/2004	2M	4/6/2004	51	9/6/2004	2	5/6/2004	1M	Y	Y	Y
TO PTO W/CERT THIS DATE.													
	N	FILE IDS/PCT SRCH	1/31/2005	3M	4/30/2005		4/30/2005	0	3/3/2005	0M	Y	Y	Y
TO PTO W/CERT THIS DATE PER MARSHA.													
SC	N	STATUS CHECK	10/30/2003	18M	4/30/2005		4/30/2005	0	4/19/2005	1M	Y	Y	Y
	N	FILE IDS/EPO SEARCH	3/13/2006	3M	6/13/2006		6/13/2006	0	6/2/2006	0M	Y	Y	Y
SEE FILE AVSI-0027WO/EP (LETTER FROM ASSOC. DATED 3/22/06 AND EPO SUPPLEMENTAL SEARCH MAILED 3/13/06). FILE ANY REFERENCES NOT ALREADY FILED. TO PTO W/CERT THIS DATE PER TRACY.													

INVENTORS

Draghia-Akli, Ruxandra

Schwartz, Robert J.

PRIOR APPLICATIONS

REFERENCE#	CNTRY	SERIAL#	FILED	TITLE / DESCRIPTION	TYPE
108328.0085	US	60/423,536	11/4/2002	(AVSI-0027PRO) SYNTHETIC MUSCLE PROMOTERS WITH ACTIVITIES EXCEEDING NATURALLY OCCURRING REGULATORY SEQUENCES IN CARDIAC CELLS	APPL

USER-DEFINABLE FIELDS

TXT1	
TXT2	
TXT3	

PATENT FIELDS

SMALL ENTITY		ART UNIT	
CLAIMS		EXAMINER	
PUBLICATION#		CONFIRM#	

P02065US01 ENTERED 11/3/2003 MODIFIED 6/2/2006 BY DAP ATTORNEYS TLC / CC / DAP